To identify the determinants of cancer immunogenicity, anti-CTLA-4 and anti-PD-1 antibody responses were predicted using the IPS.[16] As a result, IPS, IPS-CTLA4, IPS- PD1, and IPS-PD1-CTLA4 blocker scores were all significantly lower in the high-risk subgroup (P < .05; Fig. 13A–D), which indicated a worse immunotherapeutic benefit for BR patients in the high-risk subgroup. The gene discussed is CTLA4; the disease is cancer.